Success Metrics

Clinical Success Rate
44.4%

Based on 4 completed trials

Completion Rate
44%(4/9)
Active Trials
3(23%)
Results Posted
150%(6 trials)
Terminated
5(38%)

Phase Distribution

Ph phase_3
3
23%
Ph phase_4
5
38%
Ph not_applicable
3
23%
Ph phase_2
2
15%

Phase Distribution

0

Early Stage

2

Mid Stage

8

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
5(38.5%)
N/ANon-phased studies
3(23.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

44.4%

4 of 9 finished

Non-Completion Rate

55.6%

5 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(4)
Terminated(5)
Other(1)

Detailed Status

Terminated5
Completed4
Recruiting3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
44.4%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (15.4%)
Phase 33 (23.1%)
Phase 45 (38.5%)
N/A3 (23.1%)

Trials by Status

completed431%
terminated538%
unknown18%
recruiting323%

Recent Activity

3 active trials
Showing 5 of 13
recruitingnot_applicable

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

NCT07461545
recruitingnot_applicable

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

NCT07461532
completedphase_4

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

NCT04168203
recruitingphase_4

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

NCT06523959
completedphase_3

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

NCT04650087
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT07461545Not Applicable

Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS

Recruiting
NCT07461532Not Applicable

Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD

Recruiting
NCT04168203Phase 4

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Completed
NCT06523959Phase 4

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

Recruiting
NCT04650087Phase 3

COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis

Completed
NCT04142658Phase 3

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Terminated
NCT05304455Not Applicable

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

Completed
NCT04746339Phase 4

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

Terminated
NCT04498273Phase 3

COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80

Terminated
NCT04106700Phase 2

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Terminated
NCT04489849Phase 4

Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

Unknown
NCT03196349Phase 4

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

Terminated
NCT03251482Phase 2

A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13